Proteochemometric modeling of the bioactivity spectra of HIV-1 protease inhibitors by introducing protein-ligand interaction fingerprint

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Huang, Qi ^a   Jin, Haixiao ^b   Liu, Qi ^a   Wu, Qiong ^c   Kang, Hong ^a   Cao, Zhiwei ^a   Zhu, Ruixin ^a,c  

^a TONGJI UNIVERSITY   (China)

^b NINGBO UNIVERSITY   (China)

^c LIAONING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DARUNAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LIGAND; NELFINAVIR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; TMC 126; UNCLASSIFIED DRUG; XV 638;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; BIOLOGICAL MODEL; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIGAND BINDING; MULTIDRUG RESISTANCE; PREDICTION; PROTEIN BINDING; PROTEIN LIGAND INTERACTION FINGERPRINT; PROTEIN TARGETING; PROTEOCHEMOMETRIC MODELING;

HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; LIGANDS; MODELS, STATISTICAL; PROTEIN BINDING; PROTEOMICS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84864398892     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041698     Document Type: Article

References (58)

1. Dieffenbach CW, Fauci AS, (2011) Thirty years of HIV and AIDS: future challenges and opportunities. Ann Intern Med 154: 766-771.
2. Cohen J, (2011) HIV prevention. Halting HIV/AIDS epidemics. Science 334: 1338-1340.
3. Clavel F, Hance AJ, (2004) HIV Drug Resistance. New England Journal of Medicine 350: 1023-1035.
4. Ragno R, Mai A, Sbardella G, Artico M, Massa S, et al. (2004) Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin- 4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. J Med Chem 47: 928-934.
5. Ragno R, Frasca S, Manetti F, Brizzi A, Massa S, (2005) HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies. J Med Chem 48: 200-212.
6. Cichero E, Buffa L, Fossa P, (2011) 3,4,5-Trisubstituted-1,2,4-4H-triazoles as WT and Y188L mutant HIV-1 non-nucleoside reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses. J Mol Model 17: 1537-1550.
7. Wang RR, Gao YD, Ma CH, Zhang XJ, Huang CG, et al. (2011) Mangiferin, an anti-HIV-1 agent targeting protease and effective against resistant strains. Molecules 16: 4264-4277.
8. Namba AM, Da Silva VBAR, Borges Ramos TMIT, Vermelho RBON, Baptista NZAN, et al. (2009) Virtual Screening and Toxicology Prediction of Novel Potential Non- Nucleoside Reverse Transcriptase Inhibitors. Current Bioactive Compounds 5: 128-136.
9. Jayatilleke PR, Nair AC, Zauhar R, Welsh WJ, (2000) Computational studies on HIV-1 protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models. J Med Chem 43: 4446-4451.
10. Hu R, Doucet JP, Delamar M, Zhang R, (2009) QSAR models for 2-amino-6-arylsulfonylbenzonitriles and congeners HIV-1 reverse transcriptase inhibitors based on linear and nonlinear regression methods. Eur J Med Chem 44: 2158-2171.
11. Zhu R, Wang F, Liu Q, Kang T, (2011) Quantitative Structure-Activity Relationship of IOPY/ISPY Analogues as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Acta Chim Sinica 69: 1731-1736.
12. Stahura FL, Bajorath J, (2004) Virtual screening methods that complement HTS. Comb Chem High Throughput Screen 7: 259-269.
13. Liu Q, Che D, Huang Q, Cao Z, Zhu R, (2010) Multi-target QSAR Study in the Analysis and Design of HIV-1 Inhibitors. Chin J Chem 28: 1587-1592.
14. Liu Q, Zhou H, Liu L, Chen X, Zhu R, et al. (2011) Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study. BMC Bioinformatics 12: 294.
15. De Martino G, La Regina G, Ragno R, Coluccia A, Bergamini A, et al. (2006) Indolyl aryl sulphones as HIV-1 non-nucleoside reverse transcriptase inhibitors: synthesis, biological evaluation and binding mode studies of new derivatives at indole-2-carboxamide. Antivir Chem Chemother 17: 59-77.
16. Sotriffer CA, Dramburg I, (2005) "In situ cross-docking" to simultaneously address multiple targets. J Med Chem 48: 3122-3125.
17. Warren GL, Andrews CW, Capelli AM, Clarke B, LaLonde J, et al. (2006) A critical assessment of docking programs and scoring functions. J Med Chem 49: 5912-5931.
18. Leach AR, Shoichet BK, Peishoff CE, (2006) Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J Med Chem 49: 5851-5855.
19. Kitchen DB, Decornez H, Furr JR, Bajorath J, (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 3: 935-949.
20. Perola E, Walters WP, Charifson PS, (2004) A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins 56: 235-249.
21. Moitessier N, Englebienne P, Lee D, Lawandi J, Corbeil CR, (2008) Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. Br J Pharmacol 153 (Suppl 1): S7-26.
22. Junaid M, Lapins M, Eklund M, Spjuth O, Wikberg JE, (2010) Proteochemometric modeling of the susceptibility of mutated variants of the HIV-1 virus to reverse transcriptase inhibitors. PLoS One 5: e14353.
23. Lapins M, Wikberg JE, (2009) Proteochemometric modeling of drug resistance over the mutational space for multiple HIV protease variants and multiple protease inhibitors. J Chem Inf Model 49: 1202-1210.
24. Lapins M, Eklund M, Spjuth O, Prusis P, Wikberg JE, (2008) Proteochemometric modeling of HIV protease susceptibility. BMC Bioinformatics 9: 181.
25. Lapinsh M, Prusis P, Lundstedt T, Wikberg JE, (2002) Proteochemometrics modeling of the interaction of amine G-protein coupled receptors with a diverse set of ligands. Mol Pharmacol 61: 1465-1475.
26. Lapinsh M, Prusis P, Uhlen S, Wikberg JE, (2005) Improved approach for proteochemometrics modeling: application to organic compound-amine G protein-coupled receptor interactions. Bioinformatics 21: 4289-4296.
27. Lapins M, Wikberg JE, (2010) Kinome-wide interaction modelling using alignment-based and alignment-independent approaches for kinase description and linear and non-linear data analysis techniques. BMC Bioinformatics 11: 339.
28. Strombergsson H, Daniluk P, Kryshtafovych A, Fidelis K, Wikberg JE, et al. (2008) Interaction model based on local protein substructures generalizes to the entire structural enzyme-ligand space. J Chem Inf Model 48: 2278-2288.
29. Strombergsson H, Kryshtafovych A, Prusis P, Fidelis K, Wikberg JE, et al. (2006) Generalized modeling of enzyme-ligand interactions using proteochemometrics and local protein substructures. Proteins 65: 568-579.
30. Strömbergsson H, Lapins M, Kleywegt GJ, Wikberg JES, (2010) Towards Proteome-Wide Interaction Models Using the Proteochemometrics Approach. Mol Inf 29: 499-508.
31. van Westen GJP, Wegner JK, Ijzerman AP, van Vlijmen HWT, Bender A, (2011) Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets. MedChemComm 2: 16-30.
32. Sato T, Honma T, Yokoyama S, (2010) Combining machine learning and pharmacophore-based interaction fingerprint for in silico screening. J Chem Inf Model 50: 170-185.
33. (2009) Molecular Operation Environment. 2009.10 ed Montreal, Quebec, Canada Chemical Computing Group Inc.
34. Huang D, Kang H, Zhang DF, Sheng Z, Liu Q, et al. (2011) Comparison of Ligand-, Target Structure-, and Protein-Ligand Interaction Fingerprint-based Virtual Screening Methods. ACTA CHIMICA SINICA 69: 515-522.
35. Kang H, Sheng Z, Zhu R, Huang Q, Liu Q, et al. (2012) Virtual Drug Screen Schema Based on Multiview Similarity Integration and Ranking Aggregation. J Chem Inf Model.
36. Witten IH, Frank E, Hall MA, (2011) Data Mining: Practical Machine Learning Tools and Techniques (Third Edition) San Francisco Morgan Kaufmann pp. 217-223.
37. Yao XJ, Panaye A, Doucet JP, Zhang RS, Chen HF, et al. (2004) Comparative study of QSAR/QSPR correlations using support vector machines, radial basis function neural networks, and multiple linear regression. J Chem Inf Comput Sci 44: 1257-1266.
38. Isa D, Blanchfield P, Chen ZY, (2009) Intellectual Property Management System for the Super-Capacitor Pilot Plant. the proceddings of IC-AIProceedings of the 2009 International Conference on Artificial Intelligence, ICAI 2009 Las Vegas Nevada, USA CSREA Press pp. 708-714.
39. Liangpei Z, Xin H, Bo H, Pingxiang L, (2006) A pixel shape index coupled with spectral information for classification of high spatial resolution remotely sensed imagery. Geoscience and Remote Sensing, IEEE Transactions on 44: 2950-2961.
40. Muller KR, Ratsch G, Sonnenburg S, Mika S, Grimm M, et al. (2005) Classifying 'drug-likeness' with kernel-based learning methods. J Chem Inf Model 45: 249-253.
41. Muzammil S, Ross P, Freire E, (2003) A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry 42: 631-638.
42. Sandberg M, Eriksson L, Jonsson J, Sjostrom M, Wold S, (1998) New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids. J Med Chem 41: 2481-2491.
43. Labute P, (2000) A widely applicable set of descriptors. J Mol Graph Model 18: 464-477.
44. Xu J, Stevenson J, (2000) Drug-like index: a new approach to measure drug-like compounds and their diversity. J Chem Inf Comput Sci 40: 1177-1187.
45. Deng Z, Chuaqui C, Singh J, (2004) Structural interaction fingerprint (SIFt): A novel method for analyzing three-dimensional protein-ligand binding interactions. Journal of Medicinal Chemistry 47: 337-344.
46. Perez-Nueno VI, Rabal O, Borrell JI, Teixido J, (2009) APIF: A New Interaction Fingerprint Based on Atom Pairs and Its Application to Virtual Screening. Journal of Chemical Information and Modeling 49: 1245-1260.
47. Kar P, Knecht V, (2012) Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir. Journal of Computer-Aided Molecular Design 26: 215-232.
48. Kar P, Knecht V, (2012) Origin of Decrease in Potency of Darunavir and Two Related Antiviral Inhibitors against HIV-2 Compared to HIV-1 Protease. Journal of Physical Chemistry B 116: 2605-2614.
49. Cai YF, Schiffer CA, (2010) Decomposing the Energetic Impact of Drug Resistant Mutations in HIV-1 Protease on Binding DRV. Journal of Chemical Theory and Computation 6: 1358-1368.
50. Swanson JMJ, Henchman RH, McCammon JA, (2004) Revisiting free energy calculations: A theoretical connection to MM/PBSA and direct calculation of the association free energy. Biophysical Journal 86: 67-74.
51. Vays VK, Jain A, Ghate M, Maliwal D, (2011) QSAR modeling of some substituted alkylidenepyridazin-3-one as a non-cAMP-based antiplatelet agent. Medicinal Chemistry Research 20: 355-363.
52. Gupta L, Patel A, Karthikeyan C, Trivedi P, (2010) QSAR studies on dihydro-alkoxy-benzyl-oxopyrimidines (DABOs) derivatives, a new series of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors. Journal of Current Pharmaceutical Research 01: 19-25.
53. Jamloki A, Karthikeyan C, Moorthy NSHN, Trivedi P, (2006) QSAR analysis of some 5-amino-2-mercapto-1,3,4-thiadiazole based inhibitors of matrix metalloproteinases and bacterial collagenase. Bioorganic & Medicinal Chemistry Letters 16: 3847-3854.
54. Wensing AMJ, van Maarseveen NM, Nijhuis M, (2010) Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral Research 85: 59-74.
55. Ghosh AK, Dawson ZL, Mitsuya H, (2007) Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorganic & Medicinal Chemistry 15: 7576-7580.
56. Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG, (2005) Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Research 68: 27-35.
57. Yoshimura K, Kato R, Kavlick MF, Nguyen A, Maroun V, et al. (2002) A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. Journal of Virology 76: 1349-1358.
58. Ala PJ, Huston EE, Klabe RM, Jadhav PK, Lam PY, et al. (1998) Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities. Biochemistry 37: 15042-15049.